Study of an experimental drug for relapsed b-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-phase trial tests an experimental drug called STR-P004 in people with certain types of B-cell lymphoma that have come back or not responded to standard treatments. The goal is to check the drug's safety and see if it helps shrink or control the lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of B-cell lymphoma (like DLBCL, PMBCL, transformed follicular lymphoma, or high-grade B-cell lymphoma) that has come back or not responded to treatment.
- You have tried at least two prior treatments, or you had a stem cell transplant and the lymphoma returned within 12 months.
- You are generally well enough to be up and about (ECOG score of 0-2) and expected to live more than 3 months.
- Your blood counts, liver, kidney, and heart function meet minimum levels.
- You do not have active infections like hepatitis B, hepatitis C, HIV, or other serious illnesses that would make the trial unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, GLB-002, for people with non-Hodgkin lymphoma that has come back or hasn't responded to other treatments. The goal is to see if GLB-002 is safe and whether it can help shrink or control the lymphoma.
This trial tests a new drug called STR-P004 for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), a type of blood cancer. The goal is to see if the drug is safe and can help shrink or control the cancer.
This study tests an experimental drug called STR-P005 for people with diseases that affect B cells, such as certain autoimmune or blood disorders. The goal is to see if the drug is safe and if it helps reduce your disease symptoms.
This trial tests an experimental drug, SP-3164, for people with certain types of non-Hodgkin's lymphoma that have come back or not responded to prior treatments. The goal is to see if the drug can help shrink or control the cancer.
This study tests a new treatment (STR-P005) for autoimmune diseases. It aims to selectively target and deplete B cells that carry a specific marker, CD19, which may help reduce disease activity.
This trial tests an experimental drug, SAR448501/DR-0201, for people with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. The goal is to see if the drug is safe and can shrink tumors.
Hear when a new Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.